PGNYProgyny Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Peter Anevski

Location

New York, USA

Exchange

Nasdaq

Website

https://progyny.com

Summary

Progyny, Inc.

Company Info

CEO

Peter Anevski

Location

New York, USA

Exchange

Nasdaq

Website

https://progyny.com

Summary

Progyny, Inc.

AI Insights for PGNY
5 min read

Quick Summary

Progyny, Inc. is a U.S.-based healthcare benefits company focused on fertility, family-building, and reproductive health solutions for employers. The company sells benefit-management programs that combine member concierge support, access to a curated fertility specialist network, and reimbursement solutions for services such as fertility treatment, surrogacy, and adoption. Its main customers are employers that want to offer fertility and family-building benefits as part of broader employee health and retention programs. Progyny’s model is designed to help employers improve access, reduce fragmentation, and create a more predictable benefits experience for employees. The company operates in the healthcare services sector and does not currently pay a dividend, instead reinvesting cash flow into growth initiatives, product expansion, and share repurchases.

Strengths

•

Progyny’s primary strength is its specialized position in fertility and family-building benefits, a market where employers increasingly want high-quality, differentiated solutions.

•

The company has demonstrated strong client retention, which suggests that employers find value in its service model and that recurring revenue visibility is relatively good.

•

Progyny also has a solid profitability profile, with positive net income, strong adjusted EBITDA, meaningful operating cash flow, and no reported debt in recent news.

•

Its concierge-style member support and curated fertility specialist network help differentiate it from more generic healthcare benefits administrators.

•

The company’s expansion into menopause and broader reproductive health gives it a path to deepen employer relationships and increase its addressable market.

Key Risks

•

A major risk for Progyny is that employer demand could soften if companies reduce benefits spending during economic slowdowns or labor-market weakness.

•

The company also faces competitive risk from Carrot Fertility, Maven Clinic, WINFertility, Kindbody, and broader healthcare benefit platforms that may bundle similar services.

•

If covered lives decline more than expected or utilization weakens, revenue growth and operating leverage could come under pressure.

•

Regulatory, reimbursement, and healthcare cost trends may also affect employer willingness to offer or expand fertility and reproductive health benefits.

What to Watch

During the most recently discussed quarter, Progyny reported results that beat expectations, including revenue growth and stronger-than-expected EPS and EBITDA.
Q4 revenue was reported at $298.4 million in one news item, up 10.6%, while EPS of $0.42 exceeded expectations and helped trigger a strong positive share-price reaction.
The company also reported record full-year 2025 revenue of $1.29 billion, adjusted EBITDA of $222 million, and $210 million in operating cash flow.
Management highlighted near-100% client retention, a debt-free balance sheet, and continued share repurchases as important signs of financial strength.
The quarter also included strategic progress in product expansion, including reproductive health benefits for perimenopause and menopause care through Gennev and Midi Health.

Price Drivers

•

Progyny’s stock price is driven primarily by revenue growth, employer client retention, covered lives, utilization, profitability, and cash-flow performance.

•

Recent news has highlighted record annual revenue, strong adjusted EBITDA, substantial operating cash flow, no debt, and ongoing buybacks, all of which can support investor confidence.

•

At the same time, guidance pointing to lower covered lives and slowing growth can pressure valuation because the stock has historically been priced as a growth company.

•

Valuation is another major driver, as the shares have at times traded at elevated earnings multiples compared with broader healthcare averages, making the stock sensitive to earnings revisions and risk appetite.

•

Broader market trends, including investor appetite for mid-cap growth stocks, healthcare services names, and profitable companies with strong free cash flow, can also influence near-term price action.

Recent News

•

Recent news has been broadly focused on Progyny’s strong financial performance, slowing growth profile, and product expansion.

•

The company reported record 2025 revenue of $1.29 billion, adjusted EBITDA of $222 million, and $210 million in operating cash flow, while also emphasizing no debt and ongoing buybacks.

•

Progyny beat Q4 expectations, with revenue up 10.6% to $298.4 million and EPS of $0.42, which helped the stock rise sharply after results.

•

Management guided 2026 revenue to $1.355 billion to $1.405 billion and noted expectations for lower covered lives but steady utilization.

•

The company also announced an expansion into perimenopause and menopause care through Gennev and Midi Health, giving employer clients another reproductive health benefit to offer employees.

Market Trends

•

Progyny is affected by several broad trends in healthcare, employee benefits, and mid-cap growth investing.

•

Employers are increasingly using specialized health benefits, including fertility, family-building, and women’s health support, to improve retention and differentiate compensation packages.

•

At the same time, medical cost inflation and tighter corporate budgets can make employers more selective about benefits spending and vendor selection.

•

The healthcare services market is also seeing more digital health and virtual care solutions, which increases both the opportunity for platform expansion and the competitive intensity.

•

In public markets, mid-cap growth stocks can benefit when investor appetite broadens beyond mega-cap technology, but stocks with premium valuations remain highly sensitive to earnings guidance and growth expectations.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on PGNY

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show